Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Short-term Investments (2016 - 2021)

Aptevo Therapeutics (APVO) has disclosed Short-term Investments for 6 consecutive years, with $1.3 million as the latest value for Q3 2021.

  • Quarterly Short-term Investments fell 50.72% to $1.3 million in Q3 2021 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Sep 2021, down 50.72% year-over-year, with the annual reading at $2.6 million for FY2020, N/A changed from the prior year.
  • Short-term Investments hit $1.3 million in Q3 2021 for Aptevo Therapeutics, roughly flat from $1.3 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $73.7 million in Q4 2017 to a low of $1.3 million in Q1 2021.
  • Historically, Short-term Investments has averaged $18.6 million across 5 years, with a median of $7.5 million in 2018.
  • Biggest five-year swings in Short-term Investments: surged 64.3% in 2017 and later plummeted 89.89% in 2018.
  • Year by year, Short-term Investments stood at $73.7 million in 2017, then tumbled by 89.89% to $7.4 million in 2018, then rose by 0.67% to $7.5 million in 2019, then plummeted by 65.92% to $2.6 million in 2020, then tumbled by 50.72% to $1.3 million in 2021.
  • Business Quant data shows Short-term Investments for APVO at $1.3 million in Q3 2021, $1.3 million in Q2 2021, and $1.3 million in Q1 2021.